基因变异对血APOL1的平台依赖性影响
Qingbo S Wang1, Jinguo Huang1, Leanne J G Chan1
1Calico Life Sciences LLC, South San Francisco, CA, USA.
iScience
|March 2, 2026
概括
在阿波利波蛋白L1 (APOL1) 的遗传变异影响脏疾病的风险. 不同的蛋白质组学方法在APOL1水平上产生了相互矛盾的结果,这表明影响检测的形状变化.
科学领域:
- 遗传学 是一个遗传学.
- 蛋白质组学是指蛋白质组学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 阿波利波蛋白L1 (APOL1) 基因变异与非洲血统个体的脏疾病有关.
- 了解APOL1的作用需要分析其循环水平和遗传影响.
研究的目的:
- 调查在不同祖先之间循环APOL1水平的遗传驱动因素.
- 为了比较使用三个不同的蛋白质组技术的APOL1测量.
主要方法:
- 在非洲和欧洲祖先队伍中分析APOL1遗传变异和血蛋白水平.
- 用了Olink,SomaLogic和质谱仪进行蛋白质分子分析.
- 进行了定量性质位点 (QTL) 分析,以确定遗传关联.
主要成果:
- 与疾病相关的APOL1变体 (G1,G2) 作为cis-pQTLs,通过Olink和SomaLogic检测到的血APOL1,但不是质谱.
- 蛋白质组平台显示了APOL1变体的相反效果方向.
- 卡利克莱恩-基宁系统变体对奥林克表现出了跨pQTL的影响,但对索马逻辑没有.
结论:
- 检测APOL1的蛋白质基平台差异突出了对蛋白质构成的敏感性.
- 内在的APOL1突变和外在的kallikrein-kinin系统活动可能会改变APOL1的结构.
- 这些构造变化在蛋白质组测试中对APOL1检测有不同的影响.
相关概念视频
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
80
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
80
01:27Principles of Pharmacogenetics: Types of Genetic Variants
60
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
60
01:27Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68